Trials / Recruiting
RecruitingNCT07180264
Trastuzumab Deruxtecan in Advanced Breast Cancer
Trastuzumab Deruxtecan in Patients With Advanced Breast Cancer: a Real-world Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 118 (estimated)
- Sponsor
- Wenjin Yin · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab deruxtecan | Trastuzumab deruxtecan is a combination of the targeted cancer drug trastuzumab (also known as Herceptin) and a chemotherapy drug called deruxtecan or DXd. |
Timeline
- Start date
- 2025-08-28
- Primary completion
- 2027-02-01
- Completion
- 2029-02-01
- First posted
- 2025-09-18
- Last updated
- 2025-11-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07180264. Inclusion in this directory is not an endorsement.